中文摘要：

免疫抑制剂目前仍然是自身免疫病和移植排斥反应的主要治疗方法，但是它能非特异性地抑制患者对肿瘤和感染的抵抗能力。选择性清除抗原表位特异性T细胞理论上能减缓T细胞介导的病理作用，同时能保留机体的整体免疫功能状态。近年来，MHC四聚体技术和杀伤性人工抗原递呈细胞技术被用来靶向清除抗原特异性T细胞，以pMHC复合体为靶向分子，特异性结合表位特异性T细胞，同时利用放射性同位素、毒性蛋白或负调节分子等杀伤T细胞。体外实验和动物体内实验的良好结果预示着这些技术在自身免疫病、变态反应、T细胞肿瘤和移植排斥反应的治疗中有着潜在的应用前景。

英文摘要：

Immunosuppressive drugs dominate the current therapeutic landscape of autoimmune disorders and graft rejection. However, non-specific immune-ablation treatments compromise the ability of the host to respond to tumor and infection, whereas the selective removal of antigen-specific T cells could theoretically a- meliorate T-cell-mediated pathology and preserve the rest of the host immune function. During recent years, major histocompatibility complex （MHC） tetramers and killer artificial antigen-presenting cells have been used to deplete antigen-specific T ceils. Epitope-specific T cells are targeted by MHC/peptide complexes, followed by killing with radioisotope, toxin or inhibitory molecules. The promising results obtained in vitro and in animal models demonstrated their therapeutic potency for the treatment of autoimmune diseases, allergic diseases, T- cell malignancies and graft rejection.